Role of anthracyclines in the era of targeted therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
De Vita, V. T., & Chu, E. (2003). Drug development. Principles and Practice in Oncology. Philadelphia, Lippincott, 354.
Weiss, R. B., Sarosy, G., Clagett-Carr, K., Russo, M., & Leyland-Jones, B. (1986). Anthracycline analogs: The past, present, and future. Cancer Chemotherapy Pharmacology, 18, 185–197.
Verweij, J., & Kees Nooter (2002). Principles of Chemoterapy. Oxford, 564.
Hortobagyi, G. N. (1997). Anthracyclines in the treatment of cancer: An overview. Drugs, 54(Suppl 4), 1–7.
Zunino, F., & Capranico, G. (1992). DNA topisomerasas II as the primary target of antitumoral anthracyclines. Anticancer Drug Designs, 5, 307–317.
Doroshow, J. (2001). Anthracyclines and anthracenediones. Cancer chemotherapy & Biotherapy, 13, 500–537.
Friche, E., Skovsgaardt, T., & Nissen, J. I. (1989). Anthracycline resistance. Acta Oncologia, 28, 877–881.
Buzdar, A. U. (2006). Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. Journal of Clinical Oncology, 24, 2409–2411.
Bonadona, G., & DeLena, M. (1975). Combination usage of Adriamycin (NSC-123127) in malignant Lymphoma. Cancer Chemotherapy Reports, 6, 381–388.
Sledge, G. W., Neuberg, D., & Bernardo, P., et al (2003). Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). Journal of Clinical Oncology, 21(4), 588–592.
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and pharmacology developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56(2), 185–229.
Steinherz, L. J., Steinherz, P. G., Tan, C. T. C., & Heller, G. (1991). Cardiac toxicity 4 to 20 years after completing anthracyclines therapy. JAMA 266, 1672–1677.
Von Hoff, D. D., Layard, M. W., & Basa, P (1979). Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine, 91, 710–717.
Seidman, A., Hudis, C., & Pierri, M. K. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of Clinical Oncology, 20, 1215–1221.
Elliot, P. (2006). Pathogenesis of cardiotoxicity induced by anthracyclines. Seminars in Oncology, 33, S2–S7.
Marty, M., Espie, M., Llombart, A., Monnier, A., Rapoport, B.L., & Stahalova, V., Dexrazoxane Study Group. (2006). Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Annals of Oncology, 17, 614–622.
Cvtovic, R. C., & Scott, L. J. (2005). Dexrazoxane: A review of its use for cardioprotection during anthracycline chemotherapy. Drugs, 65, 1005–1012.
Northfelt, D. W., Dezube, B. J., & Thommes, J. A., et al (1998). Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: Results of a randomized phase III clinical trial. Journal of Clinical Oncology, 16, 2445–2451.
Working, P. K., Newman, M. S., & Huang, S. K., et al (1994). Pharmacokinetics biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (Doxil). Journal of Liposome Research, 4, 667–687.
Cheung, T. W., Remick, S. C., Azarnia, N., Proper, J. A., Barrueco, J. R., & Dezube, B. J. (1999). AIDS-related Kaposi’s sarcoma: A phase II study of liposomal doxorubicin. The TLC D-99 Study Group. Clinical Cancer Research, 5, 3432–3437.
Sturzl, M., Zietz C., Eisenburg, B., Goebel, F. D., Gillitzer, R., Hofschneider, P. H., & Bogner, J. R. (1994). Liposomal doxorubicin in the treatment of AIDS-associated Kaposi’s sarcoma: Clinical, histological and cell biological evaluation. Research in Virology, 145, 261–269.
Johnston, S. R. D., & Gore, M. E. (2001). Caelyx: Phase II studies in ovarian cancer. European Journal of Cancer, 37, S8–S14.
Coleman, R. E., Biganzoli, L., & Canney, P. et al (2006). A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). European Journal of Cancer, 42, 882–887.
Lyass, O., Uziely, B., & Ben-Yosef, R. et al (2000). Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer, 89, 1037–1047.
O´Byrne, K. J., Thomas, A. L., & Sharma, R. A., et al (2002). A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. British Journal of Cancer, 87, 15–20.
Valero, V., & Hortobagyi, G. N. (2003). Are anthracyclines-taxane regimens the new standard of care in the treatment of metastatic breast cancer? Journal of Clinical Oncology, 21, 959–962.
Giani, L., Vigano, L., & Locatelli, A., et al (1997). Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. Journal of Clinical Oncology, 15, 1906–1915.
Minotti, G., Saponiero, A., & Licata, S., et al (2001). Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clinical Cancer Research, 7, 1511–1515.
Nabholtz, J. M., Falkson, C., & Campos, D., et al (2003). Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. Journal of Clinical Oncology, 21, 968–975.